{"id":"W4407636125","doi":"10.1016/j.ejca.2025.115306","title":"Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; PharmaMar; Swedish Orphan Biovitrum; Seagen; Mersana Therapeutics; Clovis Oncology; AstraZeneca; Novocure; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Tarveda Therapeutics; Ludwig Institute for Cancer Research; Pfizer; Incyte; MSD Italia; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Intuitive Surgical; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ovarian cancer; Oncology; Medicine; Internal medicine; Randomized controlled trial; Phase (matter); Cancer; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002597588,0.0005928032,0.0009228121,0.0002497882,0.000160606,0.0006514743,0.000347522,0.0006683698,0.001761521],"category_scores_gemma":[0.001568256,0.0002102364,0.001252735,0.0003407886,0.0004472061,0.0004842577,0.0002230135,0.001338252,0.0002511434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007383437,"about_ca_system_score_gemma":0.0007405818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007083353,"about_ca_topic_score_gemma":0.002398035,"domain_scores_codex":[0.9994112,0.0003803978,0.00003167137,0.00005794704,0.00006458063,0.00005419203],"domain_scores_gemma":[0.9989926,0.000284802,0.0003630417,0.00005936064,0.00005337347,0.0002469033],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9003716,0.007079005,0.01003556,0.0007099856,0.001924993,0.00009147639,0.00009211923,0.00139842,0.006701682,0.0002239196,0.004040283,0.06733108],"study_design_scores_gemma":[0.8058769,0.1494545,0.03455899,0.0001164126,0.002058472,0.0002187996,0.00005558537,0.001247282,0.001438535,0.0004304829,0.004510456,0.00003362016],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861304,0.008443962,0.0004059798,0.000829704,0.000128891,0.0009381098,0.001337818,0.00003582306,0.001749343],"genre_scores_gemma":[0.9899273,0.004016775,0.0008588943,0.0009768381,0.000201106,0.0007260179,0.002120868,0.00002541466,0.001146889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002597588,"threshold_uncertainty_score":0.0137375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01890757481348089,"score_gpt":0.3472415377581165,"score_spread":0.3283339629446356,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}